Featured Press Releases

Telix

Telix's TLX250-CDx: First Patient Dosed in Italian Early Access Program for Kidney Cancer Imaging

Theravance Biopharma completes enrollment in Phase 3 CYPRESS study of Ampreloxetine for neurogenic orthostatic hypotension

Theravance Biopharma completes enrollment in Phase 3 CYPRESS study of Ampreloxetine for neurogenic orthostatic hypotension

  • 25 Aug 2025

Theravance Biopharma, Inc. announced completion of enrollment in the open-label portion of its...

VETIGEL is now available through all major U.S. distributors of veterinary products and services

VETIGEL is now available through all major U.S. distributors of veterinary products and services

FDA approves Apellis

FDA approves Apellis' EMPAVELI® (pegcetacoplan) as the first treatment for patients aged 12 and older with C3G and primary IC-MPGN

Hyalex Orthopaedics Reports Treatment of First Patients with Novel HYALEX® Knee Cartilage System

Hyalex Orthopaedics Reports Treatment of First Patients with Novel HYALEX® Knee Cartilage System

Tonix Pharmaceuticals presented Phase 3 RESILIENT data on TONMYA™ (cyclobenzaprine HCl sublingual tablets) at the 2026 Non-Opioid Pain Therapeutics Summit

Tonix Pharmaceuticals presented Phase 3 RESILIENT data on TONMYA™ (cyclobenzaprine HCl sublingual tablets) at the 2026 Non-Opioid Pain Therapeutics Summit

FDA Grants KORU Medical Systems 510(k) Clearance for RYSTIGGO® Delivery via FreedomEDGE® Infusion System

FDA Grants KORU Medical Systems 510(k) Clearance for RYSTIGGO® Delivery via FreedomEDGE® Infusion System

  • KORU Medical Systems, Inc.
  • 02 Feb 2026
Tonix Pharmaceuticals presented Phase 3 RESILIENT data on TONMYA™ (cyclobenzaprine HCl sublingual tablets) at the 2026 Non-Opioid Pain Therapeutics Summit

Tonix Pharmaceuticals presented Phase 3 RESILIENT data on TONMYA™ (cyclobenzaprine HCl sublingual tablets) at the 2026 Non-Opioid Pain Therapeutics Summit

  • Tonix Pharmaceuticals Holding Corp.
  • 30 Jan 2026
China approves Libevitug, first-in-class therapy for hepatitis D

China approves Libevitug, first-in-class therapy for hepatitis D

  • Huahui Health Ltd.
  • 28 Jan 2026
DARZALEX FASPRO® quadruplet approved in U.S. for transplant-ineligible multiple myeloma patients

DARZALEX FASPRO® quadruplet approved in U.S. for transplant-ineligible multiple myeloma patients

  • Johnson & Johnson
  • 27 Jan 2026
Correction — Privo Technologies

Correction — Privo Technologies

  • Privo Technologies
  • 26 Jan 2026
HanchorBio Partners with WuXi Biologics to Advance Next-Generation Fusion Protein Pipeline

HanchorBio Partners with WuXi Biologics to Advance Next-Generation Fusion Protein Pipeline

  • HanchorBio Inc.
  • 26 Jan 2026
World Drug Delivery Summit 2025
The Digital Pharma Advances Conference 2026

Most Popular
February   2026
M T W T F S S
            1
2 3 4 5 6 7 8
9 10 11 12 13 14 15
16 17 18 19 20 21 22
23 24 25 26 27 28  

User Area

Discover

Engage with Us

© Pharmaceutical Era — A product of HISSM. All Rights Reserved.